We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

68 hedge funds and large institutions have $1.21B invested in ARS Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

10% more funds holding

Funds holding: 62 → 68 (+6)

9.33% more ownership

Funds ownership: 70.26% → 79.6% (+9.3%)

7% more capital invested

Capital invested by funds: $1.13B → $1.21B (+$79.1M)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
68
Holders Change
+6
Holders Change %
+9.68%
% of All Funds
1.19%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
29
Increased
12
Reduced
12
Closed
23
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$65.5M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$49M
3
BlackRock
BlackRock
New York
+$39.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$13.6M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$9.72M

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$10.1M
2
LGM
Logos Global Management
California
-$8.28M
3
Citadel Advisors
Citadel Advisors
Florida
-$6.4M
4
Millennium Management
Millennium Management
New York
-$6.12M
5
Goldman Sachs
Goldman Sachs
New York
-$4.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
76
Pinz Capital Management
New York
– -$1.87M -40,300 Closed
FM
77
Frazier Management
Washington
– -$1.66M -35,750 Closed
SB
78
Samsara BioCapital
California
– -$1.16K -25,000 Closed
ECM
79
ExodusPoint Capital Management
New York
– -$968K -20,882 Closed
Qube Research & Technologies (QRT)
80
Qube Research & Technologies (QRT)
United Kingdom
– -$903K -19,484 Closed
Jane Street
81
Jane Street
New York
– -$882K -19,038 Closed
Wellington Management Group
82
Wellington Management Group
Massachusetts
– -$641K -13,837 Closed
SG Americas Securities
83
SG Americas Securities
New York
– -$598K -12,900 Closed
TEE
84
Tibra Equities Europe
United Kingdom
– -$598K -12,900 Closed
MFS
85
Mirabella Financial Services
United Kingdom
– -$525K -11,340 Closed
MS
86
Maven Securities
Jersey
– -$386K -8,333 Closed
Norges Bank
87
Norges Bank
Norway
– -$232K -5,000 Closed
PHK
88
Point72 Hong Kong
Hong Kong
– -$205K -4,422 Closed
Morgan Stanley
89
Morgan Stanley
New York
– -$110K -2,365 Closed
DKCM
90
Davidson Kempner Capital Management
New York
– -$46K -1,000 Closed
SOW
91
State of Wyoming
Wyoming
– +$426 +9 New
1 2 3
4

SPRY Hedge Fund Activity: Q1 2021 in Review

68 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q1 2021, worth a combined $1.21B — up 7% from $1.13B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new SPRY positions and 23 closed out — a net gain of 6 holders — while 12 added to existing stakes and 12 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $65.5M. The largest seller was Nantahala Capital Management, cutting an estimated $10.1M.

  • 68 institutional investors held ARS Pharmaceuticals (SPRY) as of Q1 2021, up from 62 in Q4 2020.
  • Funds reported $1.21B of ARS Pharmaceuticals stock for Q1 2021, up 7% quarter-over-quarter.
  • 29 funds opened new ARS Pharmaceuticals positions in Q1 2021 and 23 closed out, a net change of +6 holders.
  • The largest ARS Pharmaceuticals buyer in Q1 2021 was Fidelity Investments, an estimated $65.5M added.
  • The largest ARS Pharmaceuticals seller in Q1 2021 was Nantahala Capital Management, an estimated $10.1M sold.

Based on aggregated 13F filings for Q1 2021.